Lataa...
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
PURPOSE: Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on corrected QT interval using Fridericia’s formula (QTcF). METHODS: Eligible patients with advanced solid tumors received...
Tallennettuna:
| Julkaisussa: | Cancer Chemother Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5083757/ https://ncbi.nlm.nih.gov/pubmed/27709282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3156-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|